Package Leaflet: Information for the User
Epivir 150mg film-coated tablets
lamivudine
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the pack
Epivir is used in the treatment of HIV (Human Immunodeficiency Virus) infection in adults and children.
The active substance of Epivir is lamivudine. Epivir is a type of medicine known as an antiretroviral. It belongs to a group of medicines called nucleoside analogue reverse transcriptase inhibitors (NRTIs).
Epivir does not completely cure HIV infection; it reduces the amount of virus in the body and keeps it at a low level. It also increases the number of CD4 cells in the blood. CD4 cells are a type of white blood cell that plays an important role in helping your body fight infection.
Not everyone responds to treatment with Epivir in the same way. Your doctor will monitor the effectiveness of your treatment.
Do not take Epivir
Consult your doctorif you think this applies to you.
Be cautious with Epivir
Some people who take Epivir or other combination treatments for HIV infection have a higher risk of serious side effects. You need to know that there is a higher risk:
Consult your doctorif you have any of these conditions. You may need to have extra tests, including blood tests, while taking this medicine (see section 4).
Be aware of important symptoms
Some people who take medicines for HIV infection develop other conditions, which can be serious. You need to know what important signs and symptoms to look out for while taking Epivir.
Read the information under the heading “Other possible side effects of combination therapy for HIV” in section 4 of this leaflet.
Other medicines and Epivir
Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including those obtained without a prescription, and herbal medicines.
Remember to tell your doctor or pharmacist if you start taking any new medicines while taking Epivir.
The following medicines must not be used with Epivir:
Tell your doctorif you are being treated with any of these medicines.
Pregnancy
If you are pregnant, if you become pregnant, or if you are planning to become pregnant, talk to your doctor about the risks and benefits of taking Epivir for both you and your baby.
Epivir and similar medicines may cause side effects in babies during pregnancy.
If you have been taking Epivirduring your pregnancy, your doctor may ask you to have regular blood tests and other diagnostic tests to monitor the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit of protection against HIV was greater than the risk of side effects.
Breast-feeding
It is not recommendedthat women with HIV breast-feed their babies because HIV infection can be passed on to the baby through breast milk.
A small amount of the components of Epivir may also pass into breast milk.
If you are breast-feeding or thinking of breast-feeding, you should consult your doctor as soon as possible.
Driving and using machines
Epivir is unlikely to affect your ability to drive or use machines.
Epivir contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose unit; this is essentially “sodium-free”.
Follow exactly the instructions for administration of this medicine given by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.
Swallow the Epivir tablets with a little water. Epivir can be taken with or without food.
If you cannot swallow the tablets whole, you can break them and mix them with a small amount of food or liquid; take the whole dose immediately.
Stay in regular contact with your doctor
Epivir helps to control your condition. You will need to take it every day to prevent your condition from getting worse. You may develop other infections and illnesses associated with HIV infection.
Stay in contact with your doctor and do not stop taking Epivirwithout talking to your doctor first.
How much to take
Adults, adolescents, and children weighing at least 25 kg:
The usual dose of Epivir is 300 mg per day. It can be taken as one 150 mg tablet twice a day (approximately 12 hours apart), or as two 150 mg tablets once a day, as directed by your doctor.
Children weighing between 20 kg and less than 25 kg:
The usual dose of Epivir is 225 mg per day. It can be given as 75 mg (half a 150 mg tablet) in the morning and 150 mg (one whole tablet) in the evening, or 225 mg (one and a half 150 mg tablets) once a day, as directed by your doctor.
Children weighing between 14 kg and less than 20 kg:
The usual dose of Epivir is 150 mg per day. It can be taken as 75 mg (half a 150 mg tablet) twice a day (approximately 12 hours apart), or 150 mg (one 150 mg tablet) once a day, as directed by your doctor.
Epivir is also available as an oral solution for the treatment of children over 3 months and for patients who cannot swallow tablets or who require a lower dose.
If you or your child have kidney problems, your dose may need to be changed.
Consult your doctorif this applies to you or your child.
If you take more Epivir than you should
If you take more Epivir than you should, tell your doctor or pharmacist, or contact the nearest hospital emergency department. If possible, show them the Epivir packaging.
If you forget to take Epivir
If you forget to take a dose, take it as soon as you remember and then continue with your normal treatment schedule.
Do not take a double dose to make up for forgotten doses.
During treatment for HIV, you may experience an increase in weight and levels of glucose and lipids in the blood. This may be partly due to the recovery of your health and lifestyle, and in the case of lipids in the blood, sometimes to the HIV medicines themselves. Your doctor will monitor these changes.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
When you are being treated for HIV, it can be difficult to tell whether a symptom is a side effect of Epivir or of other medicines you are taking, or if it is due to the HIV disease itself. Therefore, it is very important that you inform your doctor about any changes in your health.
In addition to the side effects listed below for Epivir, other conditions can develop during combination therapy for HIV.
It is important that you read the information under the heading “Other possible side effects of combination therapy for HIV”.
Common side effects
May affect up to 1 in 10people:
Uncommon side effects
May affect up to 1 in 100people:
The uncommon side effects that may appear in blood tests are:
Rare side effects
May affect up to 1 in 1,000people:
A rare side effect that may appear in blood tests is:
Very rare side effects
May affect up to 1 in 10,000people:
A very rare side effect that may appear in blood tests is:
If you experience side effects
Tell your doctor or pharmacistif you think any of the side effects you are experiencing are serious or if you notice any side effects not listed in this leaflet.
Other possible side effects of combination therapy for HIV
Combination therapies like Epivir can cause other conditions to develop during treatment for HIV.
Worsening of old infections
People with advanced HIV infection (AIDS) have weak immune systems and are more likely to develop serious infections (opportunistic infections). When these people start treatment, they may find that old, hidden infections flare up, causing signs and symptoms of inflammation. These symptoms are probably due to an improvement in the body's immune response, which enables it to fight off these infections.
In addition to these opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you have started taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after the start of treatment. If you notice any symptoms such as muscle weakness, weakness in the hands and feet, and moving up towards the trunk of the body, palpitations, tremor, or hyperactivity, please inform your doctor immediately so that you can receive the necessary treatment.
If you notice any symptoms of infection while taking Epivir:
Tell your doctor immediately. Do not take any other medicine for the infection without your doctor's advice.
You may have problems with your bones
Some people who receive combination therapy for HIV may develop a condition called osteonecrosis. With this condition, part of the bone tissue dies due to a lack of blood supply to the bone. People are more likely to develop this condition:
Signs of osteonecrosis include:
If you notice any of these symptoms:
Tell your doctor.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the carton.
Do not store Epivir above 30°C.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Epivir
The active ingredient is lamivudine.
The other components are:
Appearance of Epivir and Package Contents
Epivir 150 mg film-coated tablets are supplied in white polyethylene bottles or blisters containing 60 tablets. The tablets are white, scored, and have a diamond shape with the code "GXCJ7" engraved on both sides.
Marketing Authorization Holder and Manufacturer
Manufacturer | Marketing Authorization Holder |
Delpharm Poznan Spólka Akcyjna ul. Grunwaldzka 189 60-322 Poznan Poland | ViiV Healthcare BV Van Asch van Wijckstraat 55H 3811 LP Amersfoort Netherlands |
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Belgium/Belgique/Belgien ViiV Healthcare srl/bv Tel: + 32 (0)10 85 65 00 | Lithuania ViiV Healthcare BV Tel: + 370 80000334 |
Bulgaria ViiV Healthcare BV Tel: + 359 80018205 | Luxembourg/Luxemburg ViiV Healthcare srl/bv Belgium/Belgien Tel: + 32 (0)10 85 65 00 |
Czech Republic GlaxoSmithKline s.r.o. Tel: + 420 222 001 111 cz.info@gsk.com | Hungary ViiV Healthcare BV Tel: + 36 80088309 |
Denmark GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00 dk-info@gsk.com | Malta ViiV Healthcare BV Tel: + 356 80065004 |
Germany ViiV Healthcare GmbH Tel: + 49 (0)89 203 0038-10 viiv.med.info@viivhealthcare.com | Netherlands ViiV Healthcare BV Tel: + 31 (0) 33 2081199 |
Estonia ViiV Healthcare BV Tel: + 372 8002640 estonia@gsk.com | Norway GlaxoSmithKline AS Tlf: + 47 22 70 20 00 |
Greece GlaxoSmithKline Μονοπρ?σωπη A.E.B.E. Tel: + 30 210 68 82 100 | Austria GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 at.info@gsk.com |
Spain Laboratorios ViiV Healthcare, S.L. Tel: + 34 900 923 501 es-ci@viivhealthcare.com | Poland GSK Services Sp. z o.o. Tel: + 48 (0)22 576 9000 |
France ViiV Healthcare SAS Tel: + 33 (0)1 39 17 6969 Infomed@viivhealthcare.com | Portugal VIIVHIV HEALTHCARE, UNIPESSOAL, LDA. Tel: + 351 21 094 08 01 viiv.fi.pt@viivhealthcare.com |
Croatia ViiV Healthcare BV Tel: +385 800787089 | Romania ViiV Healthcare BV Tel: + 40 800672524 |
Ireland GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955000 | Slovenia ViiV Healthcare BV Tel: + 386 80688869 |
Iceland Vistor hf. Tel: +354 535 7000 | Slovak Republic ViiV Healthcare BV Tel: + 421 800500589 |
Italy ViiV Healthcare S.r.l. Tel: + 39 (0)45 7741600 | Finland GlaxoSmithKline Oy Tel: + 358 (0)10 30 30 30 |
Cyprus ViiV Healthcare BV Tel: + 357 80070017 | Sweden GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 info.produkt@gsk.com |
Latvia ViiV Healthcare BV Tel: + 371 80205045 | United Kingdom (Northern Ireland) ViiV Healthcare BV Limited Tel: + 44 (0)800 221441 customercontactuk@gsk.com |
Date of the last revision of this prospectus:{MM/AAAA}.
Detailed information about this medication is available on the European Medicines Agency website: http://www.ema.europa.eu